Company Overview
Glaukos Corporation operates as an ophthalmic pharmaceutical and medical technology company focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal diseases within the United States and international markets. The firm specializes in offering iStent and iStent inject W micro-bypass stents specifically designed to treat mild-to-moderate conditions within the ophthalmology sector. This entity is categorized under the Healthcare sector and the Medical Devices industry, a classification that defines its regulatory environment, competitive landscape, and the specific patient populations it serves. The company demonstrates significant scale with a market capitalization of $5.93B, annual revenue of $507.44M, and an employee count of 1094. These valuation and revenue figures indicate that Glaukos Corporation holds a substantial market position relative to many peers in the medical device space, suggesting established distribution channels and a recognized product portfolio within the specialized field of ophthalmic care.
Financial Health
The company reported revenue of $507.44M and an EBITDA of $-48.64M over the trailing twelve months, while net income stood at $-187.69M. The substantial gap between the positive revenue figure and the large negative net income reveals a heavy cost structure characterized by high operating expenses that erode profitability significantly before reaching the bottom line. Despite the net loss, the company generated free cash flow of $1.40M, which provides a measure of financial flexibility by indicating that operational cash generation exceeds capital expenditures in the current period. Profitability metrics show a gross margin of 78.0%, indicating strong pricing power or high value in the cost of goods sold, contrasted sharply by an operating margin of -18.9% and a profit margin of -37.0%. The wide divergence between the gross margin and the operating/profit margins highlights significant overhead costs, likely related to research and development or sales and marketing, that are currently consuming the majority of gross profits. Regarding liquidity and leverage, the company holds $278.76M in cash against $106.55M in debt, resulting in a debt-to-equity ratio of 16.24. While the debt-to-equity ratio appears numerically high, the conservative balance sheet is supported by a robust cash position that significantly exceeds total debt obligations. The current ratio stands at 4.69, which indicates a very strong short-term liquidity position where current assets are more than four times current liabilities, ensuring the ability to meet immediate financial obligations. Return metrics show a return on equity of -26.4% and a return on assets of -5.8%, revealing that management is currently generating negative returns on both shareholder equity and the total asset base due to the company's net loss position.
Valuation Assessment
Valuation multiples for Glaukos Corporation include a trailing P/E ratio of N/A and a forward P/E of 252.06, where the absence of a trailing multiple reflects the current unprofitability while the elevated forward multiple implies market expectations for significant future earnings improvement. The price-to-book ratio is 8.95, indicating that the market values the company at nearly nine times its book value, suggesting a high premium assigned to the intangible assets, proprietary technology, and future growth potential rather than current tangible assets. Alternative valuation metrics include a price-to-sales ratio of 11.68 and an EV/EBITDA of -118.30, which suggests the market is pricing the stock primarily on revenue growth rather than current earnings power or cash flow generation. Price action shows a 52-week high of $130.23 and a 52-week low of $73.16, meaning the current price sits within this trading range but fluctuates based on market sentiment regarding the company's pipeline and clinical trial results. The beta value is 0.74, which indicates that the stock's price volatility is lower than the broader market, suggesting the stock is less sensitive to general market swings and may offer a more stable price profile relative to high-beta peers.
Growth & Income
Revenue growth year-over-year is recorded at 35.7%, while earnings growth is listed as N/A due to the company's current net loss position. Since earnings growth cannot be calculated numerically against prior earnings, the focus remains on the robust top-line expansion, which implies that the business is scaling its commercial operations faster than its historical profitability levels. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, indicating that it reinvests all available earnings and cash reserves into research, development, and market expansion strategies. The overall growth and income profile is defined by aggressive revenue expansion and zero dividend distribution, positioning the company as a growth-oriented investment rather than an income-generating vehicle for conservative portfolios.